Partnership Forms to Commercialize Five Biosimilars in Europe
Alvotech and Advanz Pharma have signed a strategic partnership agreement for the supply and commercialization of five biosimilar candidates in Europe.
BillionPhotos.com - stock.adobe.com
Global biotech, Alvotech, and UK pharma company, Advanz Pharma, have signed a strategic partnership agreement for the supply and commercialization of five biosimilar candidates in Europe, it was announced in a May 24, 2023 press release.
Under the terms of the agreement, Advanz Pharma will gain the exclusive rights for commercialization of five biosimilars, including a biosimilar to Simponi (golimumab) and Entyvio (vedolizumab), from Alvotech. Advanz Pharma will be responsible for the registration and commercialization of the biosimilars within the European market and Alvotech will be responsible for the development and commercial supply of the biosimilars.
“We are very excited to extend our existing partnership with Advanz Pharma into additional therapeutic areas,” said Robert Wessman, chairman and CEO of Alvotech, in the press release. “The growth of our collaboration is based on a common vision and commitment to provide better patient access to more affordable biologics.”
“This partnership positions Advanz Pharma as a key future player in European biosimilars,” added Steffen Wagner, CEO of Advanz Pharma, in the press release. “It is also an important next step in Advanz’s ambition to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe.”
Source: Advanz Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
